💸 The Tape

Ten months after the first dispensary opened its doors in December 2025, Kentucky’s medical cannabis program has hit the milestone the governor’s office has been building toward: dispensaries open in all 11 licensing regions. The last piece was Eastern Kentucky, and Cresco Labs supplied it.

Cresco plants the flag in Appalachia

On Friday, Cresco celebrated the grand opening of Sunnyside Prestonsburg at 81 Glynview Plaza in Floyd County. It’s the company’s 83rd dispensary nationally, and it carries the full Kentucky-legal formulary: flower for vaporization, tinctures, topicals and edibles, all lab-tested, with online ordering for pickup through the Sunnyside platform. CEO Charlie Bachtell framed it exactly as you’d expect an MSO to frame a rural store in a new medical state: “Access is the foundation of any successful medical cannabis program.”

Strip out the press-release language and the significance is geographic. Prestonsburg sits in the heart of coal country, a region with high rates of chronic pain and opioid exposure and almost no proximity to the Lexington and Louisville corridors where the program’s first stores clustered. Governor Beshear’s announcement that “we now have dispensaries open in all 11 licensing regions throughout the commonwealth” leaned on this store specifically. For Cresco, it’s a low-cost beachhead in a limited-license state where the patient base is growing faster than the retail footprint.

The numbers at the end of month ten

Here’s where the program stands. 26 of 48 licensed dispensaries are open, up from 24 at the end of August. Of the 16 licensed cultivators, 11 are operating. Of the 10 licensed processors, 5 are online. Two testing labs are running. The state counts 46 businesses active across the supply chain, which means roughly half the licensed capacity is still sitting on paper.

Demand has outrun that buildout. Active cardholders passed 28,000, up from 24,332 in mid-August and 12,300 in July 2025, a roughly 130% year-over-year increase. More than 500 practitioners are now registered to recommend. Monthly sales were $1.87 million in July and were tracking toward $2 million in August, with October likely higher given the additional stores. Annualized, that’s a $25 to 30 million run-rate for a program that didn’t exist a year ago, with half its retail doors still closed.

Prices are falling, which is the right kind of problem. Kentucky Cannabis Industry Alliance executive director Rachel Roberts attributes the decline to new dispensaries and the arrival of 14 Kentucky-grown brands on shelves, with more coming as cultivation and processing scale. That’s a healthy supply-side story. Early-stage medical markets typically suffer from a supply chokepoint that keeps prices artificially high and patients in the illicit market. Kentucky’s cultivators came online fast enough to avoid that, and the price curve suggests the market is finding its level rather than gouging it.

The political fight that defines the next year

The commercial rollout is clean. The politics are not.

In June, Beshear used an executive order to add 15 qualifying conditions to the program, including Parkinson’s, HIV/AIDS, sickle cell, fibromyalgia, arthritis and glaucoma, after the Republican-controlled legislature declined to expand the list during the 2026 session. He simultaneously rescinded his 2022 order pardoning Kentuckians who bought medical cannabis in neighboring states, a signal that the in-state program is now the only sanctioned path.

House Majority Whip Jason Nemes responded by asking Attorney General Russell Coleman to block state agencies from cooperating with the expansion, saying that “any organization, any licensee, that participates in this unlawful expansion should be prosecuted.” Beshear called the comment a “complete lack of humanity.” The AG has not, as of this writing, moved to enforce Nemes’s reading, and licensees have continued serving patients under the expanded list. But the legal question of whether a governor can expand a legislatively defined condition list by executive order is unresolved, and the 2027 session, which convenes in January, is the venue where it gets decided.

That matters for operators because the condition list is the patient funnel. Chronic pain already dominates the registry, but the 15 new conditions widen the base materially, and a legislature that claws them back would stall growth just as the second half of the retail footprint comes online. Beshear, a term-limited Democrat with national ambitions, has every incentive to keep pushing. The GOP supermajority has every incentive to reassert control.

What’s still missing

Kentucky’s program carries structural limits that keep it medical in fact as well as name. Flower is legal but cannot be smoked, only vaporized. There are statutory caps on THC concentration for flower and concentrates and a per-serving limit on edibles. The card process requires a practitioner visit and an annual renewal, and the renewal fee waiver Beshear ordered during the pre-retail period has served its purpose. None of these are unusual for a Southern medical state, and none have stopped Florida, Pennsylvania or Ohio from building large programs under similar rules.

What would change the trajectory is the same thing that would change it everywhere: federal rescheduling. Kentucky’s licensees are medical-only operators in a medical-only state, which puts every one of them inside the Schedule III perimeter the Attorney General drew in April. They are already outside 280E. That’s a quiet advantage that makes Kentucky’s 48 retail licenses more valuable than their revenue suggests, and it’s part of why an MSO with Cresco’s balance-sheet constraints is still spending capex in Prestonsburg.

The read

Kentucky is doing what a well-designed limited-license medical market is supposed to do. Supply came online before demand overwhelmed it. Prices are compressing from a reasonable starting point. Patient growth is running above 100% annually. And the retail buildout is half finished, which means the next twelve months of growth are already licensed and just waiting on construction.

The risk is Frankfort, not the market. If the legislature lets the expanded condition list stand, Kentucky becomes a 60,000-patient program by the end of 2027 with sales north of $75 million. If it doesn’t, the program still grows, but it grows into the ceiling the GOP built in 2023. Cresco’s Friday opening was a bet on the first scenario. The 22 operators with licenses but no open doors are making the same bet.

📺 Trade To Black

Is the Rescheduling Stay Finally Ending? | TTB Weekly Recap

• Rescheduling clears its last procedural hurdle: Judge Julius’s October 22 order admitted the GAO report but refused to reopen the hearing. Optional briefs are due October 29, replies November 5, then the stay expires. No deadline for his recommendation, and Administrator Cole’s final rule, not November 5, is what starts the clock on broader 280E relief.

• Curaleaf keeps pressing its implied $5 offer for Aurora ahead of the December 4 deadline, with Organigram reportedly circling as a potential rival bidder.

• Glass House posts record $56.8M revenue and record production, but California pricing bit: selling prices fell to $150 a pound and gross margin slipped to 26%. Rubicon Organics raised $3M from Siwash Rock to expand Pacifica output.

• Decibel faces a partial tender from Ewing Morris at $1.91 through November 6, and management and the full board say they won’t tender a single share.